9M 2023 Financial Performance

9M 2023: APPENDIX Total molecule sales (gross) - USDm ONCE-MONTHLY Trintellix Brintellix vortioxetine vortioxetine 1.500 1.250 2.000 Abilify Maintena (aripiprazole) prolonged-release suspension for injection +29% 1.600 1.000 1.200 750 800 500 250 400 0 0 2014 2015 2016 2017 2018 2019 2020 2021 2022 2014 2015 2.000 REXULTI 1.600 +67% 1.200 800 400 0 2015 2016 2017 2018 2019 2020 2021 2022 30 Source: IQVIA 2022 data (retail) 2019 2020 2021 2022 ייוון Abilify Maintena: U.S. approval (Feb. 2013); EU approval (Nov. 2013) Brintellix/Trintellix: U.S. approval (Oct. 2013); EU approval (Dec. 2013); Japan approval (Sep. 2019) Rexulti: U.S. approval (Jul. 2015); EU approval (Jul. 2018); Japan approval (Jan. 2018 – NOT Lundbeck territory) Lundbeck

View entire presentation